The median OS at 12 months was 18.21 months (95% C.I.: 7.97-NA) with 12 events occurring as reported in other studies on EGFR-mutated NSCLC patients treated with target therapy (Douillard et al. 2014). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.